{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:47:06Z","timestamp":1793832426932,"version":"4.6.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2811-B-002-168"],"award-info":[{"award-number":["NSTC 113-2811-B-002-168"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016004","name":"Institute of Biomedical Sciences, Academia Sinica","doi-asserted-by":"publisher","award":["AS-BRPT-112-01"],"award-info":[{"award-number":["AS-BRPT-112-01"]}],"id":[{"id":"10.13039\/501100016004","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03756-6","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T02:48:25Z","timestamp":1760496505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dendritic cell-targeted liposomes for cancer immunotherapy via inhibition of aryl hydrocarbon receptor"],"prefix":"10.1186","volume":"23","author":[{"given":"Chen-Guang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Yun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mridula","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian B.","family":"Abarientos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi-Ming","family":"Chiang-Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Llynard D.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungling Leo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"3756_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003013","author":"MR Jennings","year":"2021","unstructured":"Jennings MR, Munn D, Blazeck J. Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward. J Immunother Cancer. 2021;9:e003013. https:\/\/doi.org\/10.1136\/jitc-2021-003013","journal-title":"J Immunother Cancer"},{"key":"3756_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41573-025-01172-x","volume":"24","author":"CM Polonio","year":"2025","unstructured":"Polonio CM, McHale KA, Sherr DH, Rubenstein D, Quintana FJ. The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation. Nat Rev Drug Discov. 2025;24:610\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"3756_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.compbiolchem.2009.10.004","volume":"33","author":"DP Furman","year":"2009","unstructured":"Furman DP, Oshchepkova EA, Oshchepkov DY, Shamanina MY, Mordvinov VA. Promoters of the genes encoding the transcription factors regulating the cytokine gene expression in macrophages contain putative binding sites for Aryl hydrocarbon receptor. Comput Biol Chem. 2009;33:465\u20138.","journal-title":"Comput Biol Chem"},{"key":"3756_CR4","doi-asserted-by":"crossref","unstructured":"Bannwarth W, Schmidt D, Stallard RL, Hornung C, Knorr R, M\u00fcller F. Helv Chim Acta 1988, 71:2085.","DOI":"10.1002\/hlca.19880710826"},{"key":"3756_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature21080","volume":"542","author":"C Schiering","year":"2017","unstructured":"Schiering C, Wincent E, Metidji A, Iseppon A, Li Y, Potocnik AJ, Omenetti S, Henderson CJ, Wolf CR, Nebert DW, Stockinger B. Feedback control of AHR signalling regulates intestinal immunity. Nature. 2017;542:242\u20135.","journal-title":"Nature"},{"key":"3756_CR6","doi-asserted-by":"publisher","first-page":"e38384","DOI":"10.1371\/journal.pone.0038384","volume":"7","author":"C McBerry","year":"2012","unstructured":"McBerry C, Gonzalez RMS, Shryock N, Dias A, Aliberti J. SOCS2-induced proteasome-dependent TRAF6 degradation: a common anti-inflammatory pathway for control of innate immune responses. PLoS ONE. 2012;7:e38384.","journal-title":"PLoS ONE"},{"key":"3756_CR7","doi-asserted-by":"publisher","first-page":"20768","DOI":"10.1073\/pnas.1009201107","volume":"107","author":"FJ Quintana","year":"2010","unstructured":"Quintana FJ, Murugaiyan G, Farez MF, Mitsdoerffer M, Tukpah A-M, Burns EJ, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107:20768\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3756_CR8","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1016\/j.febslet.2005.10.023","volume":"579","author":"M Rodr\u00edguez-Sosa","year":"2005","unstructured":"Rodr\u00edguez-Sosa M, Elizondo G, L\u00f3pez-Dur\u00e1n RM, Rivera I, Gonzalez FJ, Vega L. Over-production of IFN-\u03b3 and IL-12 in AhR-null mice. FEBS Lett. 2005;579:6403\u201310.","journal-title":"FEBS Lett"},{"key":"3756_CR9","doi-asserted-by":"publisher","first-page":"e007495","DOI":"10.1136\/jitc-2023-007495","volume":"11","author":"C Kober","year":"2023","unstructured":"Kober C, Roewe J, Schmees N, Roese L, Roehn U, Bader B, et al. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy. J Immunother Cancer. 2023;11:e007495.","journal-title":"J Immunother Cancer"},{"key":"3756_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41467-019-08887-7","volume":"10","author":"G-Z Wang","year":"2019","unstructured":"Wang G-Z, Zhang L, Zhao X-C, Gao S-H, Qu L-W, Yu H, et al. The aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat Commun. 2019;10:1125.","journal-title":"Nat Commun"},{"key":"3756_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/eji.1830260323","volume":"26","author":"C Heufler","year":"1996","unstructured":"Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, et al. Interleukin-12 is produced by dendritic cells and mediates t helper 1 development as well as interferon-gamma production by t helper 1 cells. Eur J Immunol. 1996;26:659\u201368.","journal-title":"Eur J Immunol"},{"key":"3756_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133\u201346.","journal-title":"Nat Rev Immunol"},{"key":"3756_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.170.3.827","volume":"170","author":"M Kobayashi","year":"1989","unstructured":"Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827\u201345.","journal-title":"J Exp Med"},{"key":"3756_CR14","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1016\/j.actbio.2012.11.007","volume":"9","author":"HW Wang","year":"2013","unstructured":"Wang HW, Jiang PL, Lin SF, Lin HJ, Ou KL, Deng WP, Lee LW, Huang YY, Liang PH, Liu DZ. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. Acta Biomater. 2013;9:5681\u20138.","journal-title":"Acta Biomater"},{"key":"3756_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.actbio.2014.09.019","volume":"11","author":"PL Jiang","year":"2015","unstructured":"Jiang PL, Lin HJ, Wang HW, Tsai WY, Lin SF, Chien MY, Liang PH, Huang YY, Liu DZ. Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity. Acta Biomater. 2015;11:356\u201367.","journal-title":"Acta Biomater"},{"key":"3756_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2019.107877","volume":"487","author":"H Gao","year":"2020","unstructured":"Gao H, Gon\u00e7alves C, Gallego T, Fran\u00e7ois-Heude M, Malard V, Mateo V, et al. Comparative binding and uptake of liposomes decorated with mannose oligosaccharides by cells expressing the mannose receptor or DC-SIGN. Carbohydr Res. 2020;487:107877.","journal-title":"Carbohydr Res"},{"key":"3756_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/07328303.2024.2418524","volume":"43","author":"L Montiel","year":"2024","unstructured":"Montiel L, Spada F, Bessonov S, Crisp A, Berger C, Wiedemann S, Carell T, Frischmuth T. Synthesis and validation of clickable multimeric mannose ligands for dendritic cell targeting. J Carbohydr Chem. 2024;43:323\u201348.","journal-title":"J Carbohydr Chem"},{"key":"3756_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41577-018-0004-8","volume":"18","author":"GD Brown","year":"2018","unstructured":"Brown GD, Willment JA, Whitehead L. C-type lectins in immunity and homeostasis. Nat Rev Immunol. 2018;18:374\u201389.","journal-title":"Nat Rev Immunol"},{"key":"3756_CR19","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1073\/pnas.1805542115","volume":"115","author":"J Wu","year":"2018","unstructured":"Wu J, Wu H, An J, Ballantyne CM, Cyster JG. Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. Proc Natl Acad Sci U S A. 2018;115:6786\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3756_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.05.015","volume":"99","author":"C-Y Yeh","year":"2016","unstructured":"Yeh C-Y, Hsiao J-K, Wang Y-P, Lan C-H, Wu H-C. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. Biomaterials. 2016;99:1\u201315.","journal-title":"Biomaterials"},{"key":"3756_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, Ronneberger O, Willmore L, Ballard AJ, Bambrick J, et al. Accurate structure prediction of biomolecular interactions with alphafold 3. Nature. 2024;630:493\u2013500.","journal-title":"Nature"},{"key":"3756_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33\u20138.","journal-title":"J Mol Graph"},{"key":"3756_CR23","doi-asserted-by":"publisher","unstructured":"Evans R, O\u2019Neill M, Pritzel A, Antropova N, Senior A, Green T, \u017d\u00eddek A, Bates R, Blackwell S, Yim J et al. Protein complex prediction with AlphaFold-Multimer. bioRxiv 2021;10.04.463034. https:\/\/doi.org\/10.1101\/2021.10.04.463034","DOI":"10.1101\/2021.10.04.463034"},{"key":"3756_CR24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/bioinformatics\/btq066","volume":"26","author":"J Xu","year":"2010","unstructured":"Xu J, Zhang Y. How significant is a protein structure similarity with TM-score\u2009=\u20090.5? Bioinformatics. 2010;26:889\u201395.","journal-title":"Bioinformatics"},{"key":"3756_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/jmbi.1996.0758","volume":"266","author":"I Bahar","year":"1997","unstructured":"Bahar I, Jernigan RL. Inter-residue potentials in globular proteins and the dominance of highly specific hydrophilic interactions at close separation 1 1 edited by B. Honig. J Mol Biol. 1997;266:195\u2013214.","journal-title":"J Mol Biol"},{"key":"3756_CR26","doi-asserted-by":"crossref","unstructured":"Miller BR 3rd, McGee TD Jr., Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py: an efficient program for End-State free energy calculations. J Chem Theory Comput. 2012;8:3314\u201321.","DOI":"10.1021\/ct300418h"},{"key":"3756_CR27","doi-asserted-by":"publisher","first-page":"9169","DOI":"10.1021\/jo201686e","volume":"76","author":"NM Leonard","year":"2011","unstructured":"Leonard NM, Brunckova J. In situ formation of N-Trifluoroacetoxy succinimide (TFA-NHS): one-pot formation of succinimidyl esters, N-Trifluoroacetyl amino acid succinimidyl esters, and N-Maleoyl amino acid succinimidyl esters. J Org Chem. 2011;76:9169\u201374.","journal-title":"J Org Chem"},{"key":"3756_CR28","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1039\/D1MD00015B","volume":"12","author":"L Sun","year":"2021","unstructured":"Sun L. Recent advances in the development of AHR antagonists in immuno-oncology. RSC Med Chem. 2021;12:902\u201314.","journal-title":"RSC Med Chem"},{"key":"3756_CR29","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, et al. Successful Anti-PD-1 cancer immunotherapy requires T cell-Dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity. 2018;49:1148\u2013e11611147.","journal-title":"Immunity"},{"key":"3756_CR30","doi-asserted-by":"publisher","unstructured":"Arimoto K-i, Miyauchi S, Liu M, Zhang D-E. Emerging role of Immunogenic cell death in cancer immunotherapy. Front Immunol 2024;15:1390263. https:\/\/doi.org\/10.3389\/fimmu.2024.1390263","DOI":"10.3389\/fimmu.2024.1390263"},{"key":"3756_CR31","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14:2994\u20133006.","journal-title":"Mol Oncol"},{"key":"3756_CR32","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood.V106.11.3322.3322","volume":"106","author":"CM Marden","year":"2005","unstructured":"Marden CM, North J, Anderson R, Bakhsh IA, Addison E, Pittman H, et al. CD69 is required for activated NK cell-mediated killing of resistant targets. Blood. 2005;106:3322\u20133322.","journal-title":"Blood"},{"key":"3756_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15\u201322.","journal-title":"J Immunol Methods"},{"key":"3756_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22:96.","journal-title":"Mol Cancer"},{"key":"3756_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114655","author":"E Wakamatsu","year":"2024","unstructured":"Wakamatsu E, Machiyama H, Toyota H, Takeuchi A, Hashimoto R, Kozono H, et al. Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II. Cell Rep. 2024;43:114655. https:\/\/doi.org\/10.1016\/j.celrep.2024.114655","journal-title":"Cell Rep"},{"key":"3756_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107978","volume":"99","author":"U \u0160vajger","year":"2021","unstructured":"\u0160vajger U, Te\u0161i\u0107 N, Ro\u017eman P. Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-\u03b3. Int Immunopharmacol. 2021;99:107978.","journal-title":"Int Immunopharmacol"},{"key":"3756_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","volume":"19","author":"M Liu","year":"2024","unstructured":"Liu M, Hu S, Yan N, Popowski KD, Cheng K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol. 2024;19:565\u201375.","journal-title":"Nat Nanotechnol"},{"key":"3756_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00417","volume":"4","author":"A Vasaturo","year":"2013","unstructured":"Vasaturo A, Di Blasio S, Peeters DG, de Koning CC, de Vries JM, Figdor CG, et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go. Front Immunol. 2013;4:417.","journal-title":"Front Immunol"},{"key":"3756_CR39","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1111\/cas.13703","volume":"109","author":"Y Yamamoto","year":"2018","unstructured":"Yamamoto Y, Miyazato K, Takahashi K, Yoshimura N, Tahara H, Hayakawa Y. Lung-resident natural killer cells control pulmonary tumor growth in mice. Cancer Sci. 2018;109:2670\u20136.","journal-title":"Cancer Sci"},{"key":"3756_CR40","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/cac2.12596","volume":"44","author":"J Chen","year":"2024","unstructured":"Chen J, Duan Y, Che J, Zhu J. Dysfunction of dendritic cells in tumor microenvironment and immunotherapy. Cancer Commun. 2024;44:1047\u201370.","journal-title":"Cancer Commun"},{"key":"3756_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nri.2016.55","volume":"16","author":"TBH Geijtenbeek","year":"2016","unstructured":"Geijtenbeek TBH, Gringhuis SI. C-type lectin receptors in the control of T helper cell differentiation. Nat Rev Immunol. 2016;16:433\u201348.","journal-title":"Nat Rev Immunol"},{"key":"3756_CR42","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.addr.2013.05.007","volume":"65","author":"B Lepenies","year":"2013","unstructured":"Lepenies B, Lee J, Sonkaria S. Targeting c-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev. 2013;65:1271\u201381.","journal-title":"Adv Drug Deliv Rev"},{"key":"3756_CR43","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato LF, Budhu S, Tchaicha J, Weng C-H, Gigoux M, Cohen IJ, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-kynurenine. Nat Commun. 2020;11:4011.","journal-title":"Nat Commun"},{"key":"3756_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","volume":"48","author":"C Gutierrez-Vazquez","year":"2018","unstructured":"Gutierrez-Vazquez C, Quintana FJ. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity. 2018;48:19\u201333.","journal-title":"Immunity"},{"key":"3756_CR45","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jamcollsurg.2011.12.034","volume":"214","author":"MP Rubinstein","year":"2012","unstructured":"Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, Craig DH, Salem ML, Paulos CM, Cole DJ. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012;214:700\u20137. discussion 707\u2013708.","journal-title":"J Am Coll Surg"},{"key":"3756_CR46","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","volume":"63","author":"W Lasek","year":"2014","unstructured":"Lasek W, Zago\u017cd\u017con R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63:419\u201335.","journal-title":"Cancer Immunol Immunother"},{"key":"3756_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/cdd.2014.134","volume":"22","author":"S Tugues","year":"2015","unstructured":"Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22:237\u201346.","journal-title":"Cell Death Differ"},{"key":"3756_CR48","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi G, Liuzzi AR, Hotblack A, De Feo D, N\u00fa\u00f1ez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12:444.","journal-title":"Nat Commun"},{"key":"3756_CR49","doi-asserted-by":"publisher","first-page":"6798","DOI":"10.1182\/blood-2023-180860","volume":"142","author":"M Huang","year":"2023","unstructured":"Huang M, Zhao L, Li D, Huang L, Wang J, Zhang Y. Targeted delivery of IL-12 via CD19-modified extracellular vesicles enhances CAR-T cell efficacy against lymphoma. Blood. 2023;142:6798.","journal-title":"Blood"},{"key":"3756_CR50","doi-asserted-by":"publisher","first-page":"952231","DOI":"10.3389\/fimmu.2022.952231","volume":"13","author":"Z Jia","year":"2022","unstructured":"Jia Z, Ragoonanan D, Mahadeo KM, Gill J, Gorlick R, Shpal E, Li S. IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines. Front Immunol. 2022;13:952231.","journal-title":"Front Immunol"},{"key":"3756_CR51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36\u201348.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03756-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03756-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03756-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:04:40Z","timestamp":1760501080000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03756-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3756"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03756-6","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"683"}}